Overview

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Status:
Active, not recruiting

Trial end date:
2022-04-29

Target enrollment:

Participant gender:

Summary

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Antibodies, Monoclonal
Avelumab
Immunoglobulin G